Melola Discovery

← Melola Discovery

Jurnal SINTA 1

The Efficacy and Safety of Monoclonal Antibody Treatments Against COVID-19: A Systematic Review and Meta-analysis of Randomized Clinical Trials

ACTA MEDICA INDONESIANA · Vol. 55 No. 3 (2023)

ISSN
2338-2732, 0125-9326
Terbit
2023-11-01
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: The use of monoclonal antibody as the proposed treatment of COVID-19 showed different results in various prior studies, and Efficacy remains open in literature. This study aimed to comprehensively determine the effect of monoclonal antibodies on clinical, laboratory, and safety outcomes in COVID-19 patients. Methods: Sixteen RCTs were analyzed in this meta-analysis using RevMan 5.4 to measure the pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) with 95% CIs. Results: The pooled effect of Monoclonal antibodies demonstrated efficacy on mortality risk reduction (RR=0,89 (95%CI 0.82-0.96), I2=13%, fixed-effect), Tocilizumab also show efficacy on mortality risk reduction for severe-critical disease (RR=0.90 (95%CI 0.83-0.97), I2=12%, fixed-effect)), need for mechanical ventilation (RR=0.76 (95%CI 0.62-0.94), I2=42%, random-effects), and hospital discharge (RR=1.07 (95%CI 1.00-1.14), I2=60%, random-effects). Bamlanivimab monotherapy did not reduce viral load (SMD=-0.07 (95%CI -0.21-0.07), I2=44%, fixed-effect). Monoclonal antibodies did not differ from placebo/standard therapy for hospital discharge at day 28-30 (RR=1.05 (95%CI 0.99–1.12), I2=71%, random-effects) and safety (RR=1.04 (95%CI 0.76–1.43), I2=54%, random-effects). Conclusion: Tocilizumab should be used for severe to critical COVID-19 because it is not harmful and can improve mortality risk, mechanical ventilation, and hospital discharge. Bamlanivimab-Etesevimab and REGN-COV2 reduced viral load in mild-moderate outpatients.

Kata kunci

Jaringan kolaborasi para penulis

33 penulis · 126 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Airlangga
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Tamara Nur BudiartiUniversitas Airlangga1
Arina Dery PuspitasariUniversitas Airlangga1
Diah IndrianiUniversitas Airlangga1
Soenarnatalina MelanianiUniversitas Airlangga1
Fatimatuz Zahra Oviary SatryoUniversitas Airlangga1
Lily AinaUniversitas Airlangga1
Nanda ArdiantoUniversitas Airlangga1
Melinda Putri Amelia RachmanUniversitas Airlangga1
Fauzul MeilianiUniversitas Airlangga1
Pudji LestariAfiliasi tidak diketahui1
Puguh OktavianAfiliasi tidak diketahui1
Tri Pudy AsmarawatiAfiliasi tidak diketahui1
Fauziah ArivianiAfiliasi tidak diketahui1
Raka IhsanulhajAfiliasi tidak diketahui1
Tamara TsaniaAfiliasi tidak diketahui1
Danise FebiolaAfiliasi tidak diketahui1
Naomi Lesmana PutriAfiliasi tidak diketahui1
Hotmauli SiahaanAfiliasi tidak diketahui1
Hari Basuki NotobrotoAfiliasi tidak diketahui1
Yudi Her OktavionoAfiliasi tidak diketahui1
Paulus Parholong SiahaanAfiliasi tidak diketahui1
Rizky Novita AnjaswantiAfiliasi tidak diketahui1
Yulis Setiya DewiUniversitas Airlangga1
Makhfudli MakhfudliUniversitas Airlangga1
Tintin SukartiniUniversitas Airlangga1
Lie Liana FuadiatiUniversitas Airlangga1
Arina Qona’ahUniversitas Airlangga1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">The Efficacy and Safety of Monoclonal Antibody Treatments Against COVID-19: A Systematic Review and Meta-analysis of Randomized Clinical Trials</dc:title>
	<dc:creator>Wafa, Ifan Ali</dc:creator>
	<dc:creator>Pratama, Nando Reza</dc:creator>
	<dc:creator>Budi, David Setyo</dc:creator>
	<dc:creator>Sutanto, Henry</dc:creator>
	<dc:creator>Rosyid, Alfian Nur</dc:creator>
	<dc:creator>Wungu, Citrawati Dyah Kencono</dc:creator>
	<dc:subject xml:lang="en-US">COVID-19</dc:subject>
	<dc:subject xml:lang="en-US">Meta-analysis</dc:subject>
	<dc:subject xml:lang="en-US">Monoclonal Antibody</dc:subject>
	<dc:subject xml:lang="en-US">Mortality</dc:subject>
	<dc:subject xml:lang="en-US">Viral load</dc:subject>
	<dc:subject xml:lang="en-US">pulmonology</dc:subject>
	<dc:subject xml:lang="en-US">infection</dc:subject>
	<dc:description xml:lang="en-US">Background: The use of monoclonal antibody as the proposed treatment of COVID-19 showed different results in various prior studies, and Efficacy remains open in literature. This study aimed to comprehensively determine the effect of monoclonal antibodies on clinical, laboratory, and safety outcomes in COVID-19 patients. Methods: Sixteen RCTs were analyzed in this meta-analysis using RevMan 5.4 to measure the pooled estimates of risk ratios (RRs) and standardized mean differences (SMDs) with 95% CIs. Results: The pooled effect of Monoclonal antibodies demonstrated efficacy on mortality risk reduction (RR=0,89 (95%CI 0.82-0.96), I2=13%, fixed-effect), Tocilizumab also show efficacy on mortality risk reduction for severe-critical disease (RR=0.90 (95%CI 0.83-0.97), I2=12%, fixed-effect)), need for mechanical ventilation (RR=0.76 (95%CI 0.62-0.94), I2=42%, random-effects), and hospital discharge (RR=1.07 (95%CI 1.00-1.14), I2=60%, random-effects). Bamlanivimab monotherapy did not reduce viral load (SMD=-0.07 (95%CI -0.21-0.07), I2=44%, fixed-effect). Monoclonal antibodies did not differ from placebo/standard therapy for hospital discharge at day 28-30 (RR=1.05 (95%CI 0.99–1.12), I2=71%, random-effects) and safety (RR=1.04 (95%CI 0.76–1.43), I2=54%, random-effects). Conclusion: Tocilizumab should be used for severe to critical COVID-19 because it is not harmful and can improve mortality risk, mechanical ventilation, and hospital discharge. Bamlanivimab-Etesevimab and REGN-COV2 reduced viral load in mild-moderate outpatients.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2023-11-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2406</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 55 No. 3 (2023): Acta Medica Indonesiana; 243</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2406/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2023 Ifan Ali Wafa, Nando Reza Pratama, David Setyo Budi, Henry Sutanto, Alfian Nur Rosyid, Citrawati Dyah Kencono Wungu</dc:rights>
</oai_dc:dc>